List of Excipients in Branded Drug TASCENSO ODT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cycle Pharmaceuticals Ltd	TASCENSO ODT	fingolimod lauryl sulfate	70709-062	GELATIN	2036-01-19
Cycle Pharmaceuticals Ltd	TASCENSO ODT	fingolimod lauryl sulfate	70709-062	MANNITOL	2036-01-19
Cycle Pharmaceuticals Ltd	TASCENSO ODT	fingolimod lauryl sulfate	70709-062	MEDIUM-CHAIN TRIGLYCERIDES	2036-01-19
Cycle Pharmaceuticals Ltd	TASCENSO ODT	fingolimod lauryl sulfate	70709-062	SODIUM CHLORIDE	2036-01-19
Cycle Pharmaceuticals Ltd	TASCENSO ODT	fingolimod lauryl sulfate	70709-062	SODIUM LAURYL SULFATE	2036-01-19

TASCENSO ODT Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

TASCENSO ODT is an orally disintegrating tablet containing fingolimod hydrochloride in 0.25 mg and 0.5 mg strengths. Its commercial differentiation depends less on the active ingredient, which is already available in conventional capsule and generic forms, than on rapid disintegration, taste acceptability, dose flexibility, pediatric usability, and manufacturing control at very low drug loads. The strongest excipient opportunities are taste masking, direct-compression performance, moisture control, and low-dose content uniformity.

What is TASCENSO ODT and why does its formulation matter?

TASCENSO ODT is an orally disintegrating formulation of fingolimod hydrochloride for relapsing forms of multiple sclerosis in patients aged 10 years and older. The dosage strength is weight-dependent: 0.25 mg for patients weighing 40 kg or less and 0.5 mg for patients weighing more than 40 kg.[1]

The ODT format addresses practical limitations associated with conventional capsules:

• It can be administered without water.
• It may improve use in pediatric patients and patients with swallowing difficulty.
• It enables rapid tablet breakup in the mouth.
• It creates a differentiated dosage form for a molecule with established generic competition.
• It can support dose-specific excipient and compression optimization.

Fingolimod has a narrow dose range relative to tablet mass. A 0.25 mg tablet must distribute a very small quantity of active pharmaceutical ingredient uniformly throughout the blend. That requirement makes excipient selection and process validation commercially important.

What excipients are used in TASCENSO ODT?

The publicly available prescribing information identifies mannitol, crospovidone, colloidal silicon dioxide, magnesium stearate, sucralose, and flavoring components as inactive ingredients in TASCENSO ODT.[1]

Excipient	Primary formulation role	Commercial significance
Mannitol	Diluent, mouthfeel modifier, cooling sensation	Core ODT carrier with strong patient-acceptance profile
Crospovidone	Superdisintegrant	Supports rapid tablet breakup without excessive swelling
Colloidal silicon dioxide	Glidant and flow aid	Improves low-dose blend handling and content uniformity
Magnesium stearate	Lubricant	Supports tablet ejection but requires tight control to avoid slower disintegration
Sucralose	High-intensity sweetener	Reduces bitterness and improves pediatric acceptability
Flavoring agents	Taste and sensory masking	Supports adherence and product differentiation

The formulation is consistent with a direct-compression or highly compacted ODT platform. Mannitol supplies bulk and a favorable oral texture. Crospovidone provides rapid water uptake and tablet breakup. Colloidal silicon dioxide improves powder flow, which is particularly important when the active ingredient represents a very small fraction of total tablet weight.

Which excipients create the greatest commercial opportunity?

Mannitol-based ODT platforms

Mannitol is the most commercially significant excipient in the formulation because it performs several functions at once. It provides tablet mass, improves mouthfeel, and can produce a cooling sensation during dissolution. Excipient suppliers can compete through:

• Spray-dried grades for improved flow and compressibility.
• Granulated grades for higher tablet strength.
• Low-moisture grades for improved stability.
• Particle-size-engineered grades for faster dissolution.
• Co-processed mannitol systems containing a disintegrant or binder.

The strongest opportunity is a mannitol grade that provides high hardness at low compression force while preserving rapid disintegration. Excessive compression can reduce ODT performance, while insufficient compression can produce friability and packaging failures.

Crospovidone optimization

Crospovidone is central to the disintegration mechanism. Commercial opportunities include particle-size selection, low-peroxide grades, and optimized intra-granular or extra-granular use.

For a low-dose fingolimod ODT, crospovidone must be balanced against:

• Tablet hardness.
• Friability.
• Disintegration time.
• Mouthfeel.
• Lubricant sensitivity.
• Moisture uptake.

A supplier with data showing faster disintegration at equivalent tablet strength can compete for development projects and post-approval formulation improvements.

Taste-masking systems

Fingolimod ODT products require sensory control because rapid dissolution exposes the active ingredient in the oral cavity. Sucralose and flavoring can improve acceptability, but simple sweetening may not fully control bitterness.

Potential commercial approaches include:

• Ion-exchange resin complexes.
• Polymer-based taste-masking coatings.
• Lipid or wax microparticles.
• Cyclodextrin complexes.
• Drug-loaded microparticles.
• Co-processed sweetener-flavor systems.

The preferred approach depends on the dose, tablet size, release profile, regulatory burden, and whether the taste-masking technology changes the drug's dissolution behavior.

A taste-masking system that preserves immediate-release performance has greater commercial value than one requiring a new clinical bridge. For fingolimod, a formulation change must maintain rapid and predictable exposure because the product is administered at a low dose with clinically important dose-dependent safety considerations.

How does low-dose fingolimod affect excipient strategy?

The active ingredient is present at a very low concentration. That creates four major technical risks.

Content uniformity

The blend must distribute 0.25 mg of fingolimod hydrochloride uniformly. Direct addition of the active ingredient can create segregation or localized concentration differences. Potential controls include:

• Ordered mixing.
• Carrier-based preblends.
• Geometric dilution.
• Fine-particle engineering.
• Wet granulation or dry granulation.
• In-process blend sampling.
• Near-infrared process monitoring.

A preblend strategy using mannitol or colloidal silicon dioxide can improve distribution, but it may also affect flow and segregation behavior.

Lubricant sensitivity

Magnesium stearate can reduce interparticle bonding when overmixed. Excessive lubrication can increase disintegration time and reduce tablet tensile strength. A controlled lubrication endpoint is therefore important for maintaining the ODT profile.

Moisture management

Mannitol is less hygroscopic than some alternative polyols, but ODTs remain vulnerable to moisture because porosity, flavoring, sweeteners, and disintegrants can alter water uptake. Packaging is a major part of the formulation strategy.

Commercial packaging opportunities include:

• Unit-dose aluminum-aluminum blisters.
• High-barrier cold-form foil.
• Desiccant-containing bottles.
• Child-resistant unit-dose systems.
• Calendar packs for pediatric dosing and adherence.

Mechanical robustness

ODTs must disintegrate quickly but survive packaging, transport, and removal from a blister. Excipient suppliers can differentiate through data on tensile strength, friability, ejection force, and disintegration after accelerated storage.

What formulations are protected by TASCENSO ODT?

The commercially relevant formulation space includes:

1. Fingolimod ODTs containing mannitol and crospovidone.
2. Low-dose tablets at 0.25 mg and 0.5 mg.
3. Taste-masked fingolimod compositions.
4. Rapid-disintegration formulations administered without water.
5. Pediatric dosage forms with weight-based dose selection.
6. Manufacturing processes that achieve low-dose content uniformity.
7. Packaging systems that preserve tablet integrity and dissolution performance.

The FDA label establishes the approved composition and use, but it does not by itself establish the full scope of any formulation or process patent claims.[1] Patent analysis should distinguish between claims covering the active ingredient, claims covering an ODT composition, claims covering taste masking, and claims covering a manufacturing process.

What is the FDA regulatory status of TASCENSO ODT?

TASCENSO ODT was approved by the FDA under NDA 214962 for relapsing forms of multiple sclerosis in patients aged 10 years and older.[1] The product is a small-molecule drug, not a biologic. Biosimilar pathways therefore do not apply.

Regulatory issue	TASCENSO ODT position
Active ingredient	Fingolimod hydrochloride
Dosage form	Orally disintegrating tablet
Strengths	0.25 mg and 0.5 mg
Therapeutic area	Relapsing forms of multiple sclerosis
Pediatric use	Patients aged 10 years and older
Regulatory pathway	NDA approval
Biosimilar exposure	Not applicable
Generic exposure	High, because fingolimod is a small molecule with established generic competition

The product's commercial protection depends on the interaction between FDA exclusivity, any listed patents, formulation differentiation, and commercial execution. A three-year new clinical investigation exclusivity period may be relevant where the approval relied on new clinical investigations, but exclusivity status must be confirmed in the current FDA Orange Book and exclusivity databases rather than inferred from the label.

What is the Orange Book status of TASCENSO ODT?

TASCENSO ODT should be evaluated through its NDA number, 214962, rather than through the reference-listed drug entry for Gilenya. Orange Book review should cover:

• NDA 214962.
• Any listed formulation patents.
• Any method-of-use patents.
• Pediatric exclusivity.
• Patent expiration dates.
• Paragraph IV certification activity.
• Therapeutic-equivalence codes for competing products.

The key legal distinction is between a generic fingolimod capsule and a generic fingolimod ODT. A capsule applicant may challenge the active ingredient or dosage-form claims differently from an applicant seeking an ODT. An ANDA applicant for an ODT would face greater formulation-specific exposure if TASCENSO ODT has listed patents directed to rapid disintegration, taste masking, or composition ranges.

When does TASCENSO ODT lose exclusivity?

FDA exclusivity and patent exclusivity are separate.

FDA exclusivity may restrict approval of certain competing applications for a defined period. Patent expiry can continue to delay launch after regulatory exclusivity ends. The relevant timeline should include:

Protection category	Commercial effect
New drug exclusivity	Restricts FDA approval of certain competing applications
Pediatric exclusivity	Can add six months to qualifying listed protections
Formulation patents	May delay an ODT competitor
Method-of-use patents	May require a section viii carve-out or label strategy
Manufacturing patents	May force process redesign
Trade secrets	Can increase development cost but generally do not block independent development
Trademark protection	Protects branding, not the active ingredient or dosage form

A generic company can potentially launch a competing fingolimod product after resolving listed patents through Paragraph IV litigation, a settlement, a non-infringement position, or a design-around formulation.

Which companies are challenging TASCENSO ODT?

Publicly available product information identifies TASCENSO ODT as a branded fingolimod ODT product, but a complete challenge analysis requires current FDA ANDA records, Orange Book patent listings, and federal court docket searches. Generic competition is more visible around fingolimod capsules, where multiple manufacturers have entered or pursued approval.

Potential competitors fall into four groups:

• Generic fingolimod capsule manufacturers.
• Companies developing fingolimod ODT products.
• Specialty pharmaceutical companies pursuing pediatric CNS delivery systems.
• Excipient and CDMO providers supplying ODT platforms.

The commercial threat from capsule generics is immediate because physicians and payers may view an ODT premium as discretionary. The threat from another ODT is more direct because it would target the same administration and adherence advantages.

How strong is the TASCENSO ODT patent estate?

The product's patent strength depends on whether protection covers only the specific composition or also broader technical features. Stronger claims would cover multiple commercially necessary elements, such as:

• Fingolimod concentration ranges.
• Mannitol and crospovidone combinations.
• Specific disintegration limits.
• Taste-masking architecture.
• Low-dose uniformity processes.
• Moisture-protective packaging.
• Pediatric dosing methods.

Narrow claims limited to one excipient ratio or one flavor system are easier to design around. Broader claims covering functional performance, composition ranges, and manufacturing controls are more valuable but face greater validity and written-description scrutiny.

Because fingolimod itself is established, the primary intellectual-property value is likely to reside in formulation, delivery, pediatric use, and manufacturing claims rather than basic composition-of-matter protection.

What licensing deals could support TASCENSO ODT growth?

Licensing opportunities are concentrated in five areas:

1. Taste-masking technology for bitter or low-dose molecules.
2. Co-processed mannitol and disintegrant systems.
3. Pediatric flavor and sensory platforms.
4. High-barrier blister packaging.
5. CDMO technology for low-dose direct compression.

A formulation owner could license a proprietary ODT platform to other multiple-sclerosis or pediatric products. An excipient supplier could offer a development partnership tied to volume commitments, regional rights, or technology-transfer fees.

The most defensible licensing asset would combine excipient composition, manufacturing process, and performance data. A single off-the-shelf excipient has lower switching costs and weaker negotiating leverage.

What generic launch risks exist for TASCENSO ODT?

The principal generic launch scenarios are:

Capsule substitution

Generic fingolimod capsules may capture patients who do not require an ODT. This creates payer pressure and limits the price premium for TASCENSO ODT.

ODT design-around

A competitor could use a different polyol, such as xylitol or a different mannitol grade, combined with an alternative superdisintegrant and taste-masking system. A design-around could avoid narrow composition claims.

Authorized generic or branded-generic competition

A lower-priced product using the same or similar dosage form could reduce market share without changing the clinical product profile.

Pediatric-focused competition

A competitor could target pediatric patients with mini-tablets, dispersible tablets, oral granules, or liquid formulations. These products would compete on swallowing, portability, and dosing flexibility rather than exact ODT equivalence.

What are the commercial opportunities for excipient suppliers?

The addressable opportunity is broader than TASCENSO ODT itself. The same excipient platform can support ODT products in neurology, psychiatry, pediatrics, and emergency medicine.

Highest-value opportunities include:

• Low-dose direct-compression platforms.
• Taste-masked pediatric tablets.
• Robust ODTs for unit-dose blister packaging.
• Co-processed excipients with regulatory documentation.
• Excipient systems supported by compendial status and global supply.
• Formulation packages that reduce development time for ANDA and 505(b)(2) sponsors.

Suppliers should compete on reproducibility, regulatory support, global capacity, and demonstrated performance at low drug loading. Price alone is unlikely to determine selection where content uniformity and bioequivalence risk are material.

How does TASCENSO ODT compare with conventional fingolimod products?

Attribute	TASCENSO ODT	Conventional fingolimod capsule
Administration	Dissolves in the mouth	Swallowed with water
Pediatric usability	Stronger differentiation	More dependent on swallowing ability
Excipient complexity	Higher sensory and mechanical demands	Generally lower
Generic competition	ODT-specific competition may be limited	Established generic competition
Packaging sensitivity	High	Usually lower
Taste exposure	Directly relevant	Limited
Main commercial advantage	Convenience and patient acceptability	Lower cost and established use

Key Takeaways

• TASCENSO ODT uses a conventional but commercially effective ODT excipient architecture centered on mannitol, crospovidone, colloidal silicon dioxide, magnesium stearate, sucralose, and flavoring.
• Low-dose fingolimod creates significant content-uniformity and blend-segregation risks.
• Mannitol grade selection, crospovidone optimization, taste masking, lubrication control, and moisture-barrier packaging are the main formulation levers.
• The product has small-molecule generic risk, not biosimilar risk.
• ODT-specific commercial value depends on pediatric usability, taste, rapid disintegration, and payer acceptance.
• The strongest licensing opportunities involve co-processed excipients, taste masking, low-dose manufacturing, and high-barrier packaging.
• Patent value is likely to center on formulation, process, pediatric-use, and packaging claims rather than fingolimod composition-of-matter claims.

FAQs

Can a different mannitol grade create a competitive TASCENSO ODT?

Yes. A different mannitol grade can change flow, compactability, tablet hardness, friability, mouthfeel, and disintegration. A substitute must preserve content uniformity and dissolution performance.

Is TASCENSO ODT suitable for a 505(b)(2) reformulation strategy?

Potentially. An ODT, taste-masked tablet, or pediatric dosage form may support a reformulation strategy, but the regulatory pathway depends on the proposed labeling, clinical evidence, and FDA requirements.

What is the most important excipient for fingolimod ODT taste?

No single excipient controls taste in every formulation. Sucralose and flavoring improve palatability, while a dedicated taste-masking system may be required to reduce direct exposure to fingolimod.

Can an ODT competitor avoid TASCENSO ODT patents?

A competitor may pursue a design-around using different excipients, ratios, processing conditions, taste-masking technology, or packaging. The outcome depends on the scope and validity of issued claims.

What packaging is best for TASCENSO ODT-type products?

High-barrier unit-dose blister packaging is generally the strongest commercial option where moisture, tablet friability, and dose portability are critical.

References

1. U.S. Food and Drug Administration. (2022). TASCENSO ODT (fingolimod hydrochloride) orally disintegrating tablets: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.